Company Overview and News

 
Velan Inc. Reports Its Second Quarter 2018/19 Financial Results

2018-10-11 globenewswire
MONTREAL, Oct. 11, 2018 (GLOBE NEWSWIRE) -- Velan Inc. (TSX: VLN) (the “Company”), a world-leading manufacturer of industrial valves, announced today its financial results for its second quarter ended August 31, 2018.
VLN

 
Velan Inc. Reports Its First Quarter 2018/19 Financial Results

2018-07-12 globenewswire
MONTREAL, July 12, 2018 (GLOBE NEWSWIRE) -- Velan Inc. (TSX:VLN) (the “Company”), a world-leading manufacturer of industrial valves, announced today its financial results for its first quarter ended May 31, 2018.
VLN

 
Velan Inc. : Avis

2018-07-03 globenewswire
MONTRÉAL, 03 juill. 2018 (GLOBE NEWSWIRE) -- Velan Inc. (TSX:VLN) annonce aujourd`hui que le jeudi 12 juillet 2018, elle communiquera ses résultats financiers pour le premier trimestre de l’exercice terminé le 31 mai 2018.
VLN

 
Velan Inc.: Announcement

2018-07-03 globenewswire
MONTREAL, July 03, 2018 (GLOBE NEWSWIRE) -- Velan Inc. (TSX:VLN) today announced that, on Thursday, July 12, 2018, it will release its 1st Quarter results for the fiscal year ended May 31, 2018.
VLN

 
Velan Inc.: Announcement

2018-05-17 globenewswire
MONTREAL, May 17, 2018 (GLOBE NEWSWIRE) -- Velan Inc. (TSX:VLN) today announced that, on Thursday, May 24, 2018, it will release its 4th Quarter results for the fiscal year ended February 28, 2018.
VLN

 
Velan Inc. : Avis

2018-05-17 globenewswire
MONTRÉAL, 17 mai 2018 (GLOBE NEWSWIRE) -- Velan Inc. (TSX:VLN) annonce aujourd`hui que le jeudi, 24 mai 2018, elle communiquera ses résultats financiers pour le quatrième trimestre de l’exercice terminé le 28 février 2018.
VLN

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to TSX:VLN / Velan Inc. Sv on message board site Silicon Investor.

Valence Technology- How low can it go? (VLNC) Valence Technology- How low can it go? (VLNC) Valence Technology- How low can it go? (VLNC) VALENCE TECHNOLOGY (VLNC) VALENCE TECHNOLOGY (VLNC) VALENCE TECHNOLOGY (VLNC)
HVLN Learning to the next level HVLN Learning to the next level HVLN Learning to the next level VLNT - Videolan VLNT - Videolan VLNT - Videolan
VLNK: viaLink Company VLNK: viaLink Company VLNK: viaLink Company VideoLAN (VLNT) VideoLAN (VLNT) VideoLAN (VLNT)
CSCO MSPG FDC JVLN Net Articles, Reader Highlight TD CSCO MSPG FDC JVLN Net Articles, Reader Highlight TD CSCO MSPG FDC JVLN Net Articles, Reader Highlight TD Better Batteries: VLNC and ULBI Better Batteries: VLNC and ULBI Better Batteries: VLNC and ULBI